Division of Toxicology, Office of Applied Research and Safety Assessment, Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, Laurel, MD, 20708, USA.
Department of Biomedical Engineering, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Stem Cell Res Ther. 2020 Sep 11;11(1):393. doi: 10.1186/s13287-020-01914-1.
Hepatocyte-like cells (HLCs) derived from human induced pluripotent stem cells (iPSCs) hold great promise in toxicological applications as well as in regenerative medicine. Previous efforts on hepatocyte differentiation have mostly relied on the use of growth factors (GFs) to recapitulate developmental signals under in vitro conditions. Recently, the use of small molecules (SMs) has emerged as an attractive tool to induce cell fate transition due to its superiority in terms of both quality and cost. However, HLCs derived using SMs have not been well characterized, especially on the transcriptome level.
HLCs were differentiated from human iPSCs using a protocol that only involves SMs and characterized by transcriptomic analysis using whole genome microarrays.
HLCs derived using the SM protocol (HLC_SM) displayed specific hepatic marker expression and demonstrated key hepatic functions. Transcriptomic analysis of the SM-driven differentiation defined a hepatocyte differentiation track and characterized the expression of some key marker genes in major stages of hepatocyte differentiation. In addition, HLC_SM were scored with CellNet, a bioinformatics tool quantifying how closely engineered cell populations resemble their target cell type, and compared to primary human hepatocytes (PHHs), adult liver tissue, fetal liver tissue, HLCs differentiated using GFs (HLC_GF), and commercially available HLCs. Similar to HLC_GF, HLC_SM displayed a mixed phenotype of fetal and adult hepatocytes and had relatively low expression of metabolic enzymes, transporters, and nuclear receptors compared to PHHs. Finally, the differentially expressed genes in HLC_SM compared to HLC_GF and to PHHs were analyzed to identify pathways and upstream transcription regulators which could potentially be manipulated to improve the differentiation of HLCs.
Overall, the present study demonstrated the usefulness of the SM-based hepatocyte differentiation method, offered new insights into the molecular basis of hepatogenesis and associated gene regulation, and suggested ways for further improvements in hepatocyte differentiation in order to obtain more mature HLCs that could be used in toxicological studies.
源自人诱导多能干细胞(iPSC)的肝细胞样细胞(HLC)在毒理学应用以及再生医学中具有很大的应用前景。先前的肝细胞分化研究主要依赖于生长因子(GFs)在体外条件下重编程发育信号。最近,小分子(SMs)的使用作为一种有吸引力的工具出现,因为它在质量和成本方面都具有优越性,从而可以诱导细胞命运转变。然而,使用 SMs 衍生的 HLC 尚未得到很好的表征,特别是在转录组水平上。
使用仅涉及 SM 的方案从人 iPSC 中分化 HLC,并通过全基因组微阵列进行转录组分析来进行表征。
使用 SM 方案(HLC_SM)衍生的 HLC 显示出特定的肝标志物表达,并表现出关键的肝功能。SM 驱动的分化的转录组分析定义了一个肝细胞分化轨迹,并描述了在肝细胞分化的主要阶段中一些关键标记基因的表达。此外,使用 CellNet 对 HLC_SM 进行评分,CellNet 是一种用于量化工程细胞群体与其目标细胞类型的相似程度的生物信息学工具,并与原代人肝细胞(PHH)、成人肝组织、胎肝组织、使用 GFs(HLC_GF)分化的 HLC 和商业上可用的 HLC 进行比较。与 HLC_GF 类似,HLC_SM 显示出胎儿和成人肝细胞的混合表型,并且与 PHH 相比,代谢酶、转运蛋白和核受体的表达相对较低。最后,分析 HLC_SM 与 HLC_GF 和 PHH 相比差异表达的基因,以确定可能用于改善 HLC 分化的途径和上游转录调控因子。
总体而言,本研究证明了基于 SM 的肝细胞分化方法的有用性,提供了对肝发生和相关基因调控的分子基础的新见解,并提出了进一步改善肝细胞分化的方法,以获得更成熟的 HLC,可用于毒理学研究。